PMGC Holdings (ELAB) Non Operating Interest Expenses (2022 - 2026)
PMGC Holdings' (ELAB) quarterly Non Operating Interest Expenses came in at $582241.0 in Q2 2026, up 22.79% quarter-over-quarter from $474170.0 in Q1 2026.
Analysis
PMGC Holdings (ELAB) Non Operating Interest Expenses (2022 - 2026) Analysis & Trends
PMGC Holdings has disclosed Non Operating Interest Expenses across 5 years of filings, most recently posting $582241.0 for Q2 2026.
- In Q2 2026, Non Operating Interest Expenses changed N/A year-over-year to $582241.0; the TTM figure through Jun 2026 stood at $1.3 million (changed N/A YoY), while the FY2025 annual figure was $257630.0, changed N/A from the prior year.
- Non Operating Interest Expenses came in at $582241.0 for Q2 2026 at PMGC Holdings, up from $474170.0 in the prior quarter.
- In the past five years, Non Operating Interest Expenses ranged from a high of $648332.0 in Q3 2024 to a low of -$2.6 million in Q4 2022.
- Average Non Operating Interest Expenses over 5 years is $2790.6, with a median of $78151.0 recorded in 2025.
- Year-over-year, Non Operating Interest Expenses slumped 99.12% in 2023 and surged 11248.36% in 2024.
- Over 5 years, Non Operating Interest Expenses stood at -$2.6 million in 2022, then jumped by 100.26% to $6767.0 in 2023, then jumped by 9480.79% to $648332.0 in 2024, then tumbled by 87.95% to $78151.0 in 2025, then jumped by 645.02% to $582241.0 in 2026.
- Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $582241.0 in Q2 2026, $474170.0 in Q1 2026, and $78151.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 209.77 Bn | 195.78 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.17 Bn | 176.99 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 131.81 Bn | 123.96 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.07 Bn | 74.07 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.31 Bn | 56.12 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.58 Bn | 48.44 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.65 Bn | 30.34 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.73 Bn | 30.44 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.65 Bn | 29.65 Bn | 1.16 Mn | - |
| 10 | PMGC Holdings | 2.25 Mn | -16.54 Mn | 385,691.00 | 582,241.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 582,241.00 |
| Mar 31, 2026 | 474,170.00 |
| Dec 31, 2025 | 78,151.00 |
| Sep 30, 2025 | 179,479.00 |
| Sep 30, 2024 | 648,332.00 |
| Jun 30, 2024 | 30,806.00 |
| Dec 31, 2023 | 6,767.00 |
| Sep 30, 2023 | 5,713.00 |
| Jun 30, 2023 | 4,409.00 |
| Dec 31, 2022 | -2.63 Mn |
| Sep 30, 2022 | 646,000.00 |